Across TCGA pan-cancer cohorts, RPL23A Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RPL23A data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher RPL23A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RPL23A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, BRCA, and BLCA are the cancer types where RPL23A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	IV	0.074	0.496	.002	12	view →
BRCA	OS	Median	III,IV	0.114	0.544	.035	6	view →
BLCA	DFS	Median	IV	0.126	0.479	.007	6	view →
LIHC	DFS	Median	All	0.096	0.526	.023	6	view →
UCEC	DFS	Median	All	1.000	0.624	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: RPL23A tumor-vs-normal RNA expression · all RPL23A data types